XML 67 R45.htm IDEA: XBRL DOCUMENT v3.25.4
Parent Company Balance Sheets (Tables)
 12 Months Ended
Oct. 31, 2025
Parent Company Balance Sheets [Abstract]  
Schedule of Consolidated Financial Statements

As of October 31, 2025 and 2024, there were no material contingencies, significant provisions for long-term obligations, or guarantees of the Company, except for those which have been separately disclosed in the consolidated financial statements, if any.

   October 31,
2025		   October 31,
2024		 
   US$   US$ 
ASSETS        
Current assets        
Cash and cash equivalents   291    
-
 
Other receivable   5,004    
-
 
Total current assets   5,295    
-
 
Investment in unconsolidated subsidiaries   12,481,495    7,953,227 
Total assets   12,486,790    7,953,227 
LIABILITIES          
Current liabilities          
Other payables   180,000    
-
 
Due to related parties   23,003    
 
 
Total current liabilities   203,003    
-
 
Total liabilities   203,003    
-
 
Total shareholders’ equity   12,283,787    7,953,227 
Total liabilities and shareholders’ equity   12,486,790    7,953,227 
Schedule of Condensed Statement of Income and Comprehensive Income
   October 31,
2025		   October 31,
2024		   October 31,
2023		 
   US$   US$   US$ 
Revenues   
—
    
—
    
—
 
Operating expenses               
General and administrative   (200,463)   
-
    
-
 
Loss from operations   (200,463)   
-
    
-
 
Equity method income   200,527    1,813,170    1,909,271 
Interest expense   1,962    
—
    
—
 
Income before income taxes   2,026    1,813,170    1,909,271 
Income tax expense   
—
    
—
    
—
 
Net income   2,026    1,813,170    1,909,271 
Other comprehensive loss               
Foreign currency translation difference   52,666    36,714    (39,443)
Total comprehensive income   54,692    1,849,884    1,869,828 
Schedule of Condensed Statement of Cash Flows
   October 31,
2025		   October 31,
2024		   October 31,
2023		 
   US$   US$   US$ 
Cash Flows from Operating Activities:            
Net income   2,026    1,813,170    1,909,271 
Equity method income   (253,193)   (1,849,884)   (1,869,828)
Other receivables   (5,004)   
-
    
-
 
Other payables   180,000    
-
    
-
 
Due to related parties   23,003    
-
    
-
 
Net cash used in operating activities   (53,168)   (36,714)   39,443 
Investments in subsidiary   (4,275,075)   (787,266)   
-
 
Net cash provided by investing activities   (4,275,075)   (787,266)   
-
 
Proceeds from issuance of common stock   4,275,868    787,266    
-
 
Net cash provided by financing activities   4,275,868    787,266    
-
 
Net decrease in cash and cash equivalents   (52,375)   (36,714)   39,443 
Cash and cash equivalents, beginning of year   
-
    
-
    
-
 
Effect of exchange rate changes on cash and cash equivalents   52,666    36,714    (39,443)
Cash and cash equivalents, end of year   291    -    -